Local vascular toxicokinetics of stent-based drug delivery

Toxicology Letters

Volumn 168, Issue 2, 2007, Pages 93-102

  Tesfamariam, Belay ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug delivery; Release kinetics; Restenosis; Stents; Vascular toxicity

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLINE; DRUG CARRIER; METHACRYLIC ACID; PHOSPHORYLCHOLINE; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; RAPAMYCIN; SINGLE STRANDED DNA;

ARTERY INTIMA PROLIFERATION; BIODEGRADABILITY; BLOOD VESSEL OCCLUSION; CELL MIGRATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; EARLY DIAGNOSIS; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; HUMAN; IN-STENT RESTENOSIS; MATERIAL COATING; MECHANICAL STRESS; MEDIATOR RELEASE; MOLECULAR MECHANICS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; STENOSIS; THROMBOSIS; TOXICOKINETICS; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; CORONARY RESTENOSIS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACOKINETICS; STENTS; VASCULAR DISEASES;

EID: 33846119664     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2006.11.013     Document Type: Review

References (47)

1. Axel D.L., Kunert W., Goggelmann C., Oberhoff M., Herdeg C., Kuttner A., Wild D.H., Brehm B.R., Riessen R., Koveker G., and Karsch K.R. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
2. Bertrand O.F., Sipehia R., Mongrain R., Rodes J., Tardif J.C., Bilodeau L., Cote G., and Bourassa M.G. Biocompatibility aspects of new stent technology. J. Am. Coll. Cardiol. 32 3 (1998) 562-571
3. 1 arrest in human arterial smooth muscle cells. Cell Cycle 3 8 (2004) 1050-1056
4. Blindt R., Vogt F., Astafieva I., Fach C., Hristov M., Krott N., Seitz B., Kapurniotu A., Kwok C., Dewor M., Bosserhoff A.K., Bernhagen J., Hanrath P., Hoffmann R., and Weber C. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J. Am. Coll. Cardiol. 47 9 (2006) 1786-1795
5. Carter A.J., Aggarwal M., Kopia G.A., Tio F., Tsao P.S., Kolata R., Yeung A.C., Llanos G., Dooley J., and Falotico R. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc. Res. 63 4 (2004) 617-624
6. Carter A.J., Laird J.R., Kufs W.M., Bailey L., Hoopes T.G., Reeves T., Farb A., and Virmani R. Coronary stenting with a novel stainless steel balloon-expandable stent: determinants of neointimal formation and changes in arterial geometry after placement in on atherosclerotic model. J. Am. Coll. Cardiol. 27 (1996) 1270-1277
7. Coats Jr. W.D., Whittaker P., Cheung D.T., Currier J.W., Han B., and Faxon D.P. Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation 95 5 (1997) 1293-1300
8. Creel C.J., Lovich M.A., and Edelman E.R. Arterial paclitaxel distribution and deposition. Circ. Res. 86 (2000) 879-884
9. Denis C.V., and Wagner D.D. Insights from von Willebrand disease animal models. Cell Mol. Life Sci. 56 (1999) 977-990
10. de Smet B.J., de Kleijn D., Hanemaaijer R., Verheijen J.H., Robertus L., van Der Helm Y.J., Borst C., and Post M.J. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation 101 25 (2000) 2962-2967
11. Farb A., Songiorgi G., Carter A.J., Walley V.M., Edwards W.D., Schwartz R.S., and Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation 99 (1999) 44-52
12. Farb A., Weber O.K., Kolodgie F.D., Burke A.P., and Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 105 (2002) 2974-2980
13. Finn A.V., Kolodgie F.D., Harnek J., Guerrero L.J., Acampado E., Tefera K., Skorija K., Weber D.K., Gold H.K., and Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 2 (2005) 270-278
14. Frimerman A., Welch P.J., Jin X., Eigler N., Yei S., Forrester J., Honda H., Makkar R., Barber J., and Litvack F. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 99 (1999) 697-703
15. Garasic J.M., Edelman E.R., Squire J.C., Seifert P., Williams M.S., and Rogers C. Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation 101 (2000) 812-818
16. Geary R.L., Williams J.K., Golden D., Brown D.G., Benjamin M.E., and Adams M.R. Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. A nonhuman primate model of restenosis. Arterioscler. Thromb. Vasc. Biol. 16 1 (1996) 34-43
17. Glover C., Ma X., Chen Y.X., Miller H., Veinot J., Labinaz M., and O'Brien E. Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation. Am. Heart J. 144 4 (2002) 702-709
18. Horvath C., Welt F.G., Nedelman M., Rao P., and Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ. Res. 90 (2002) 488-494
19. Hwang C.-W., Wu D., and Edelman E.R. Physiologic transport forces govern drug distribution for stent-based delivery. Circulation 104 (2001) 600-605
20. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., Kutys R., Skorija K., Gold H.K., and Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48 1 (2006) 193-202
21. Kantor B., Ashai K., Holmes Jr. D.R., and Schwartz R.S. The experimental animal models for assessing treatment of restenosis. Cardiovasc. Radiat. Med. 1 (1999) 48-54
22. Kotani J., Awata M., Nanto S., Uematsu M., Oshima F., Minamiguchi H., Mintz G.S., and Nagata S. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J. Am. Coll. Cardiol. 47 10 (2006) 2108-2111
23. Kuchulakanti P.K., Chu W.W., Torguson R., Ohlmann P., Rha S.W., Clavijo L.C., Kim S.W., Bui A., Gevorkian N., Xue Z., Smith K., Fournadjieva J., Suddath W.O., Satler L.F., Pichard A.D., Kent K.M., and Waksman R. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 8 (2006) 1108-1113
24. Lowe H.C., Fahmy R.G., Kavurma M.M., Baker A., Chesterman C.N., and Khachigian L.M. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-I in the porcine model of coronary in-stent restenosis. Circ. Res. 89 (2001) 670-677
25. Lowe H.C., Schwartz R.S., Mac Neill B.D., Jang I.-K., Hayase M., Rogers C., and Oesterie S.N. The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents. Cathet. Cardiovasc. Intervent. 60 (2003) 515-523
26. Maier W., Windecker S., Kung A., Lutolf R., Eberli F.R., Meier B., and Hess O.M. Exercise-induced coronary artery vasodilation is not impaired by stent placement. Circulation 105 20 (2002) 2373-2377
27. McFadden E.P., Stabile E., Regar E., Cheneau E., Ong A.T., Kinnaird T., Suddath W.O., Weissman N.J., Torguson R., Kent K.M., Pichard A.D., Satler L.F., Waksman R., and Serruys P.W. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 9444 (2004) 1519-1521
28. Nebeker J.R., Virmani R., Bennett C.L., Hoffman J.M., Samore M.H., Alvarez J., Davidson C.J., McKoy J.M., Raisch D.W., Whisenant B.K., Yarnold P.R., Belknap S.M., West D.P., Gage J.E., Morse R.E., Gligoric G., Davidson L., and Feldman M.D. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol. 47 1 (2006) 175-181
29. Nuhrenberg T.G., Voisard R., Fahlisch F., Rudelius M., Braun J., Gschwend J., Kountides M., Herter T., Baur R., Hombach V., Baeuerle P.A., and Zohlnhofer D. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J. 19 2 (2005) 246-248
30. Ong A.T., Aoki J., Kutryk M.J., and Serruys P.W. How to accelerate the endothelialization of stents. Arch. Mal. Cœur. Vaiss. 98 2 (2005) 123-126
31. Prati F., Di Mario C., Moussa I., Reimers B., Mallus M.T., Parma A., Lioy E., and Colombo A. In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study. Circulation 99 8 (1999) 1011-1014
32. Ranade S.V., Miller K.M., Richard R.E., Chan A.K., Allen M.J., and Helmus M.N. Physical characterization of controlled release of paclitaxel from the TAXUS Express drug eluting stent. J. Biomed. Mater. Res. 71A (2004) 625-634
33. Schwartz R.S., Chronos N.A., and Virmani R. Preclinical restenosis models and drug-eluting stents. J. Am. Coll. Cardiol. 44 (2004) 1373-1385
34. Schwartz R.S., Edelman E.R., Carter A., Chronos N., Rogers C., Robinson K.A., Waksman R., Weinberger J., Wilensky R.L., Jensen D.N., Zuckerman B.D., and Virmani R. Drug-eluting stents in preclinical studies recommended evaluation from a consensus group. Circulation 106 (2002) 1867-1873
35. Serruys P.W., Kutryk M.J., and Ong A.T. Coronary-artery stents. N. Engl. J. Med. 354 5 (2006) 483-495
36. Sousa J.E., Serruys P.W., and Costa M.A. New frontiers in cardiology. Drug-eluting stents: part I. Circulation 107 (2003) 2274-2279
37. Suzuki T., Kopia G., Hayashi S., Bailey L.R., Llanos G., Wilensky R., Klugherz B.D., Papandreou G., Narayan P., Leon M.B., Yeung A.C., Tio F., Tsao P.S., Falotico R., and Carter A.J. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104 10 (2001) 1188-1193
38. Taylor A.J., Gorman P.D., Kenwood B., Hudak C., Tashko G., and Virmani R. A comparison of four stent designs on arterial injury, cellular proliferation, neointima formation, and arterial dimensions in an experimental porcine model. Catheter. Cardiovasc. Interv. 53 (2001) 420-425
39. Togni M., Windecker S., Cocchia R., Wenaweser P., Cook S., Billinger M., Meier B., and Hess O.M. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46 2 (2005) 231-236
40. van der Giessen W.J., Lincoff A.M., Schwartz R.S., van Beusekom H.M., Serrys P.W., Holmes Jr. D.R., Ellis S.G., and Topol E.J. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries. Circulation 94 (1996) 1690-1697
41. Vetrovec G.W., Rizik D., Williard C., Snead D., Piotrovski V., and Kopia G. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. Catheter. Cardiovasc. Interv. 67 1 (2006) 32-37
42. Virmani R., Farb A., Guagliumi G., and Kolodgie F.D. Drug-eluting stents: caution and concerns for long-term outcome. Coron. Artery Dis. 15 (2004) 313-318
43. Virmani R., Guagliumi C., Farb A., Musumeci C., Grieco N., Motta T., Mihalcsik L., Tespili M., Valsecchi O., and Kolodgie F.D. Localized hypersensitivity and late coronary thrombosis secondary to a sirolirnus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
44. Virmani R., Kolodgie F.D., Farb A., and Lafont A. Drug-eluting stents: are human and animal studies comparable. Heart 89 (2003) 133-138
45. Virmani R., Liistro F., Stankovic G., Di Mario C., Montorfano M., Farb A., Kolodgie F.D., and Colombo A. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106 21 (2002) 2649-2651
46. Welt F.G., Tso C., Edelman E.R., Kjelsberg M.A., Paolini J.F., Seifert P., and Rogers C. Leukocyte recruitment and expression of chemokines following different forms of vascular injury. Vasc. Med. 8 1 (2003) 1-7
47. Wu C.H., Pan J.S., Chang W.C., Hung J.S., and Mao S.J. The molecular mechanism of actinomycin D in preventing neointimal formation in rat carotid arteries after balloon injury. J. Biomed. Sci. 12 3 (2005) 503-512